# The impact of treatment switching on healthcare resource utilization among patients with hereditary angioedema in the United States

<sup>1</sup>University of California San Diego, San Diego, CA, USA; <sup>2</sup>Division of Allergy and Clinical Immunology, David Geffen School of Medicine, USA; <sup>3</sup>CSL Behring AG, Bern, Switzerland; <sup>4</sup>CSL Behring, King of Prussia, PA, USA; <sup>5</sup>Oracle Corporation, Redwood City, CA, USA; <sup>6</sup>Division of Rheumatology, Allergy and Immunology, Department of Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.

## Continuously evolving

- 2018, and 2020<sup>1-3</sup>
- of HAE in Australia, Europe, Japan, Switzerland, and the UK<sup>4,5</sup>
- updated in 2020 and 2021<sup>6,7</sup>





### CONCLUSIONS

- Initiating or switching LTP led to a reduction in HAE attack rate

\*Patients received two LTP therapies concurrently and were not included in this analysis; †Calculated as the number of individuals with an 1. US FDA. Berotralstat Prescribing Information. Available at: https://www.accessdata.fda.gov/drugsatfda\_docs/label/2020/214094s000lbl.pdf (accessed May 2025); attack divided by the total person-time for each group (in months), expressed per 100 person-months. Attacks recorded as HAE-specific 2. US FDA. Lanadelumab Prescribing Information. Available at: https://www.accessdata.fda.gov/drugsatfda\_docs/label/2022/761090s003lbl.pdf (accessed May 2025) ER/hospital visits associated with ICD-10 code D84.1 in the primary position or ICD-10 codes associated with angioneurotic edema, swelling 3. US FDA. Haegarda Prescribing Information. Available from: https://www.fda.gov/media/105611/download (accessed May 2025); 4. CSL Behring. Available at: https://newsroom abdominal pain, or asphyxiation, OR as administration of HAE ODT; ‡Calculated as the number of individuals with a healthcare visit divided b 2-13-European-Commission-Approves-CSLs-ANDEMBRY-R-garadacimab-for-the-Prevention-of-Recurrent-Attacks-of-Hereditary-Angioedema-HAE (accessed the total person-time recorded for each group (in months), expressed per 100 person-months; <sup>s</sup>Visit-related costs excluded treatment costs. csl.com/2025 C1INH, c1 inhibitor; ER, emergency room; HAE, hereditary angioedema; HCRU, healthcare resource utilization; ICD-10, International May 2025); 5. CSL Behring. Available at: https://newsroom.csl.com/2025-02-20-CSL-Receives-Approval-in-Japan-for-ANDEMBRY-R-garadacimab-Subcutaneous-S-C-Injection-200mg-Pens,-a-Novel-Human-Anti-Activated-Factor-XII-Monoclonal-Antibody-for-the-Prevention-of-Acute-Attacks-of-Hereditary-Angioedema-HAE (accessed May 2025); 6. Busse PJ et al. J Allergy Clin Immunol Pract 2021;9:132–50.e3; 7. Maurer M et al. Allergy 2022;77:1961–1990;8. Castaldo AJ et al. Allergy Asthma Proc 2021;42:108–117. Classification of Diseases, Tenth Revision; IV, intravenous; LTP, long-term prophylaxis; ODT, on-demand treatment; rec, recombinant; SC, subcutaneous.

### Marc A. Riedl<sup>1</sup>, Raffi Tachdjian<sup>2</sup>, Chiara Nenci<sup>3</sup>, Vai Katkade<sup>4</sup>, Darcy Ellis<sup>4</sup>, Yinglei Li<sup>4</sup>, Abisola Olopoenia<sup>5</sup>, Aleena Banerji<sup>6</sup>

Switching from LTP to LTP was associated with reductions in healthcare-related visit frequency and healthcare-related costs post-switch These results highlight the importance of HAE treatment optimization to improve patient outcomes while reducing healthcare resource burden

### References



### Disclosures

This study was funded by CSL Behring LLC. Medical writing support was provided by Hazel Shepherd, DPhil, of Helix, OPEN Health Communications, and was funded by CSL Behring, in accordance with Good Publication Practice guidelines (GPP 2022).

European Academy of Allergy and Clinical Immunology Congress | Glasgow, United Kingdom | June 13 – 16 2025



